Dr. Abraham (Bram) Bout is Chief Executive Officer and Managing Director of Bioceros, a division of the Polpharma Group. Recently, Bram was VP, Head of Epirus Biopharmaceuticals (Netherlands). He was also Chief Technology Officer at Profibrix BV (Leiden, The Netherlands) from 2007 – 2014. Prior to joining Bioceros (in 2007), he was employed by Crucell (from 1993 till March 2007), where he held several management positions with increasing responsibility. His last position at Crucell was Vice President, Protein Production. Bram is co-inventor of the human PER.C6 production platform which is used for the development and manufacturing of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. He studies Chemistry at the University of Amsterdam and his PhD thesis was on peroxisomal storage disorders. He published over 50 scientific articles and is co-inventor on 90 patents about the PER.C6 cell line technology and in the field of recombinant protein production and gene therapy.
CSO, Managing Director
Dr. Boon received his Ph.D. in Biochemistry at the University of Amsterdam. He also carried out post-doctoral positions at University of Amsterdam at the Department of Anatomy and Embryology and at the Department of Clinical Epidemiology. Thereafter he was one of the founders of PanGenetics where he was responsible for project management and animal studies. Since the merger between PanGenetics and Tanox Inc. in Houston, he had the position of VP Preclinical in which he was world-wide responsible for preclinical safety assessments and animals studies for the Tanox group. Dr. Boon has performed antibody therapy for immunoinflammatory diseases both in murine and non-human primate disease models and healthy non-human primates. Thereafter Dr. Boon was one of the founders of MacroZyme BV and for 2 years Director of Preclinical R&D of MacroZyme BV, where he was responsible for a small molecule project in the metabolic field and various potential protein-based therapeutic molecules. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer (CSO). In addition he held a position as CSO for 4AZA Bioscience NV and VP Preclinical (ad interim) for PanGenetics BV until the end of 2006. He has extensive experience in molecular and cellular immunology and in therapeutic antibody development and has been involved in the trajectory of preclinical preparation and design of First into Man studies using therapeutic antibodies. Dr. Boon is author/co-author of over 200 papers in international scientific journals in the field of medical biotechnology.
COO, Managing Director
Remco Brandt holds a Master of Science degree in Management and held several scientific and management positions over the last decades in both Academic institutions and biotech companies in the Netherlands, Germany and the US. He was closely involved in the set-up of several new life science laboratories and biotech companies. He has a broad experience in operations, administration, HR and finance specifically for biotech-oriented organizations. Besides founder of Bioceros, he is also founder/managing director of Life Science Purchasing Power BV, BiocerOX Products, Ambracia Biopharmaceuticals and Cluster Therapeutics. He is also (co)-author of over 30 peer-reviewed scientific articles. For more details: www.linkedin.com/in/remcombrandt
EMILE VAN CORVEN
Dr. Emile van Corven is Chief Development Officer at Bioceros, Head of Downstream Process and Analytical development at Bioceros. Prior to joining Bioceros he was a principal consultant CMC at Xendo (2014-2015). From 2001-2014 he was employed by Crucell/J&J, where he was responsible for the USP and DSP development of MAbs and viral vaccines, and the GMP pilot plant (global). From 2000-2001 he worked for the Dutch regulatory authorities as head of control lab for the release blood products/vaccines on the European market, and head of a regulatory group for the review of CMC dossiers biological/biotechnological products for access to the European market. From 1992-2000 he worked for Pharming, where he held various positions with increasing responsibility in pharmaceutical development or recombinant proteins (DSP, analytical, Tech transfer, GMP) and project management. From 1988-1992 he was a post-doc at The Netherlands Cancer Institute in Amsterdam. He got his PhD in 1987 at Nijmegen University, and his MSc in biology/chemistry at Leiden university in 1983. He published over 30 peer-reviewed scientific articles and is co-inventor on various patents. He was member of accreditation commission to assess the quality of the PDEng program “Bioproduct designer”, Technical University Delft, Netherlands. From 2012-2015 he was member of the editorial board of “Pharmaceutical Bioprocessing” journal.
Dr. Spaninger received his PhD from molecular biology from University of Ljubljana (Slovenia) and his research fellow at Harvard Medical School (Cambridge, USA). Dr. Spaninger is a pharmaceutical professional with international experience on global project management, technical and biologics development expertise. He possesses strong team leadership qualities and strategic entrepreneurial thinking in drug development. Besides managing director at Bioceros he is since 2016 director of project management and member of management team of Polpharma Biologics (Gdansk, Poland). Before joining Polpharma he held several positions at Sandoz (Basel, Switzerland):
- 2014 – 2016 Global program manager for biosimilars
- 2013 – 2014 Head of analytical laboratories DP biosimilars
- 2012 – 2013 Technical project leader for biosimilars
Furthermore, in 2010 he was co-founder of start-up DiaGenomi (Ljubljana, Slovenia) a high-tech company that offers services and solutions in three different areas of molecular biology.
MARKUS SIEGER (CHAIRMAN)
Markus Sieger holds a degree in Economics from the University of Applied Sciences for Business and Administration in Zurich. Mr. Sieger currently holds the position of CEO and President of the Management Board Polpharma Group.
Since the mid-nineties he has built up a strong track record in successfully managing complex and strategic transactions in and outside of Poland. He was successfully managing large M&A transaction and developing multinational ventures in the area of pharmaceuticals and FMCG companies. He has already been involved in supervision and management of Polpharma Group as a member of the Supervisory Board of Polpharma, delegated to exercise individual supervision over the company since 2013.
He has a considerable experience in supervising activities of both private and public companies, being a member of several supervisory boards of which of Bioceros as chairman.
Dr. Windisch is the Chief Operating Officer at Polpharma Biologics, in charge of research & development, technical operations / manufacturing, quality, and project management. He also serves on on the Board of Directors of Oncobiologics Inc., a US-based, NASDAQ-traded biotech company.
Before joining Polpharma Biologics, he was the Chief Operating Officer at Affimed NV, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer.
Prior to that, Dr. Windisch spent almost 20 years at Novartis, where he most recently served as Chief Scientific Officer for Sandoz Biopharmaceuticals and Global Head Technical Development & Clinical Manufacturing for Novartis Biopharmaceutical Operations. He was instrumental in achieving approval for the first biosimilars in Europe and the US. He was also involved in the development and manufacturing of innovative biologics and in the company’s contract development and manufacturing business.
Dr. Windisch holds a PhD in biochemistry and numerous patents in the field of biological medicines.